NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The Company's nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic assay to be marketed through the company's diagnostics business. The system is positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

Type
Public
HQ
Seattle, US
Founded
2003
Size (employees)
407 (est)
NanoString Technologies was founded in 2003 and is headquartered in Seattle, US
Report incorrect company information

Key People/Management at NanoString Technologies

Brad Gray

Brad Gray

President and Chief Executive Officer
James Johnson

James Johnson

CFO
William Young

William Young

Executive Chairman of the Board
Wayne Burns

Wayne Burns

Senior Vice President, Operations & Administration

NanoString Technologies Office Locations

NanoString Technologies has offices in Seattle and Hong Kong
Seattle, US (HQ)
2000 530 Fairview Ave N
Show all (2)
Report incorrect company information

NanoString Technologies Financials and Metrics

NanoString Technologies Financials

NanoString Technologies's revenue was reported to be $114.91 m in FY, 2017
USD

Revenue (Q1, 2018)

23.1 m

Net income (Q1, 2018)

(19.2 m)

EBIT (Q1, 2018)

(17.9 m)

Market capitalization (15-May-2018)

284 m

Closing share price (15-May-2018)

11

Cash (31-Mar-2018)

15.6 m
NanoString Technologies's current market capitalization is $284 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

31.4 m47.6 m62.7 m86.5 m114.9 m

Revenue growth, %

52%32%38%

Cost of goods sold

15 m

Gross profit

16.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

8.4 m8.8 m10.9 m12.3 m11.6 m13.1 m15.7 m14.7 m22.6 m23.9 m18.1 m34.6 m23.1 m

Cost of goods sold

3.8 m4.3 m

Gross profit

4.6 m4.4 m

Gross profit Margin, %

55%51%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

9.9 m17.2 m21.9 m20.6 m26.1 m

Accounts Receivable

8.3 m12.4 m19.7 m22.2 m19.6 m

Inventories

6.8 m5.4 m3.9 m13.8 m20.1 m

Current Assets

60.7 m95.3 m82.8 m113.8 m121.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

19.3 m29 m21.2 m18.8 m14.3 m15.7 m16.6 m29.6 m19.3 m10.5 m5.4 m40.6 m15.6 m

Accounts Receivable

6.8 m7.4 m9.1 m15.3 m10.5 m13.2 m12.9 m15.5 m25.2 m21 m16.7 m18.5 m16.3 m

Inventories

5.7 m7.5 m6.4 m5.8 m7.9 m9.4 m11.7 m11.8 m12.5 m11.7 m14.5 m15.8 m19.1 m

Current Assets

67.5 m104.3 m99.1 m92.9 m79.3 m81.5 m74.6 m87.2 m98.5 m90.7 m92.4 m138.9 m101.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(29.3 m)(50 m)(45.6 m)(47.1 m)(43.6 m)

Depreciation and Amortization

1.8 m1.5 m2.4 m3 m3.4 m

Inventories

(1.4 m)(1.3 m)(5.4 m)(5 m)(8.7 m)

Accounts Payable

1.6 m21 k(166 k)869 k(110 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(7.7 m)(11.4 m)(14.1 m)(12.1 m)(14.9 m)(12.4 m)(9.5 m)(14.6 m)(10.8 m)(10.1 m)(18.9 m)(19.2 m)

Depreciation and Amortization

928 k

Inventories

6.4 m5.8 m7.9 m9.4 m11.7 m11.8 m12.5 m11.7 m14.5 m817 k

Accounts Payable

2.7 m2.2 m4.6 m2.4 m2.6 m3.5 m4 m2.1 m2.1 m716 k
USDY, 2018

Financial Leverage

4.7 x
Show all financial metrics
Report incorrect company information

NanoString Technologies News and Updates

Report incorrect company information